A Study of ABCD for Injection in Subjects With Invasive Candidiasis &

Status Not yet recruiting

Clinical Trial Summary

This is a multi-center, open-label, non-controlled, single-arm clinical trial to evaluate the safety, efficacy and population pharmacokinetics of Amphotericin B cholesteryl Sulfate Complex for Injection domestic formulations (ABCD) in the treatment of confirmed invasive candidiasis (IC) and confirmed/clinically diagnosed invasive aspergillus (IA) disease.

Clinical Trial Description

The study includes a screening period (day -14 to day -1), a baseline period (day 1), a treatment period, and a follow-up period (14±3 days after the end of administration). Eligible subjects will receive intravenous ABCD infusion. A test dose of 2 mg/10 mL will be given at baseline, followed by titration after the evaluation of the subjects' symptoms, signs and tolerance by investigator, until reaching the recommended dose of 3.0-4.0 mg/kg once a day for treatment. IC subjects will receive ABCD intravenous therapy for a minimum of 2 weeks, and a maximum of 14 days after the first negative turn of candida culture in blood or other normal sterile sites and the symptoms and signs of infection disappear/improve significantly, up to a maximum of 6 weeks. IA subjects will be treated with ABCD for at least 2 weeks and up to 6 weeks. After the end of intravenous therapy, according to the individual condition of the subjects, pathogens, drug sensitivity test, and the therapeutic effect of ABCD, the investigator will make a comprehensive judgment on whether to give sequential therapy drugs, but the total course of treatment shall not exceed the duration specified in the above scheme (the number of days of ABCD intravenous therapy plus the number of days of sequential therapy shall not exceed 6 weeks). The study will end when the last subject completed the follow-up period. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05707832
Study type	Interventional
Source	CSPC Ouyi Pharmaceutical Co., Ltd.
Contact	Shaoqin Xu
Phone	8618062661629
Email	xushaoqin@mail.ecspc.com
Status	Not yet recruiting
Phase	Phase 3
Start date	March 30, 2023
Completion date	December 15, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06028451` - ManagemEnt of Antifungal Drug in Invasive Aspergillosis：a Real-word Study
Completed	`NCT00163722` - A Multicentre Randomised Controlled Trial Comparing Two Strategies for the Diagnosis of Invasive Aspergillosis in High-risk Haematology Patients	Phase 3
Completed	`NCT02394483` - Single Ascending Oral Dose Study of F901318	Phase 1
Completed	`NCT00404092` - Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis	Phase 2
Completed	`NCT01128907` - Galactomannan Antigen in Bronchoalveolar Lavage in the Diagnosis of Invasive Aspergillosis in Neutropenic Patients	N/A
Recruiting	`NCT01386437` - Natural History of Individuals With Immune System Problems That Lead to Fungal Infections
Withdrawn	`NCT02912026` - Radiolabelled IV and Oral Metabolism Study of F901318	Phase 1
Withdrawn	`NCT03095547` - Drug/Drug Interactions With F901318	Phase 1
Withdrawn	`NCT03076905` - Pharmacokinetics of IV Formulation	Phase 1
Completed	`NCT02737371` - Multiple Ascending Oral Dose Study of F901318 in Healthy Subjects	Phase 1
Terminated	`NCT00836875` - A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children	Phase 3
Active, not recruiting	`NCT00838643` - Invasive Aspergillosis After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)	N/A
Terminated	`NCT04876716` - Azole-echinocandin Combination Therapy for Invasive Aspergillosis	Phase 3
Recruiting	`NCT05101187` - Olorofim Aspergillus Infection Study	Phase 3
Enrolling by invitation	`NCT02104479` - Diagnostic Accuracy of Pleural Effusion Aspergillosis Biomarker Testing
Recruiting	`NCT06382922` - Role of Antifungal Prophylaxis in Elderly Patients With Acute Myeloid Leukemia During Consolidation Therapy
Terminated	`NCT02396225` - Concentrations of Voriconazole in Blood and BAL-fluid After Inhalation and Oral Administration	N/A
Recruiting	`NCT00843804` - Surveillance for Nosocomial Infections in Pediatric Cancer Patients	N/A
Completed	`NCT00334412` - COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis	Phase 4
Completed	`NCT04550936` - Patterns of Real-World Isavuconazole Use - a Study of Patients With Mucormycosis or Invasive Aspergillosis

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms